Venturi Wealth Management LLC Buys 4,260 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Venturi Wealth Management LLC grew its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 554.7% during the fourth quarter, Holdings Channel reports. The firm owned 5,028 shares of the company’s stock after purchasing an additional 4,260 shares during the period. Venturi Wealth Management LLC’s holdings in Takeda Pharmaceutical were worth $67,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. FMR LLC increased its position in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares during the last quarter. Stifel Financial Corp increased its position in shares of Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after acquiring an additional 224,594 shares during the last quarter. Summit Global Investments increased its position in shares of Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after acquiring an additional 192,143 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after acquiring an additional 155,795 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after acquiring an additional 134,407 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $14.07 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $44.75 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 0.24 and a beta of 0.51. The stock has a 50 day moving average of $13.31 and a 200 day moving average of $13.88. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.